Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy

Chih Ching Yeh, Ching Yu Lai, Shih Ni Chang, Ling Ling Hsieh, Reiping Tang, Fung Chang Sung, Yi Kuei Lin

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: This study examined the association between methylenetetrahydrofolate reductase (MTHFR) polymorphisms and survival of patients with colorectal cancer (CRC) treated with 5-fluorouracil (5-FU)-based chemotherapy in Taiwan. Methods: We genotyped MTHFR polymorphisms C677T (rs1801133) and A1298C (rs1801131) for 498 CRC patients treated with 5-FU-based chemotherapy after receiving surgery. Survival analyses on MTHFR polymorphisms were performed using log-rank test and Kaplan–Meier curve. Cox proportional hazards models were used to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between MTHFR genotypes and survival. Results: Overall survival (OS) was significantly longer in CRC patients with MTHFR 677 CT+TT genotypes compared with those with 677 CC genotype (HR 0.77; 95% CI 0.60–0.98). Although the MTHFR A1298C polymorphism was not associated with OS in CRC, this polymorphism was associated with significantly shorter OS in rectal cancer. Among rectal cancer patients, OS was shorter for patients with AC+CC genotypes than for those with the AA genotype (HR 1.95; 95% CI 1.35–2.83). In haplotype analysis, better OS was found for colon cancer patients carrying the MTHFR 677T-1298A haplotype (HR 0.73; 95% CI 0.55–0.97), but worse survival was linked to rectal cancer patients carrying the MTHFR 677C-1298C haplotype (HR 1.53; 95% CI 1.08–2.18). Conclusions: Our findings suggest that MTHFR genotypes provide prognostic information for CRC patients treated with 5-FU-based chemotherapy.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalInternational Journal of Clinical Oncology
DOIs
Publication statusAccepted/In press - Jan 2 2017

Fingerprint

Methylenetetrahydrofolate Reductase (NADPH2)
Fluorouracil
Colorectal Neoplasms
Drug Therapy
Survival
Genotype
Confidence Intervals
Rectal Neoplasms
Haplotypes
Survival Analysis
Taiwan
Proportional Hazards Models
Colonic Neoplasms

Keywords

  • 5-Fluorouracil
  • Colorectal cancer
  • MTHFR
  • Overall survival
  • Polymorphisms

ASJC Scopus subject areas

  • Surgery
  • Hematology
  • Oncology

Cite this

Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy. / Yeh, Chih Ching; Lai, Ching Yu; Chang, Shih Ni; Hsieh, Ling Ling; Tang, Reiping; Sung, Fung Chang; Lin, Yi Kuei.

In: International Journal of Clinical Oncology, 02.01.2017, p. 1-10.

Research output: Contribution to journalArticle

@article{e54a82d27ba84cb29884a3e6ecc11773,
title = "Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy",
abstract = "Background: This study examined the association between methylenetetrahydrofolate reductase (MTHFR) polymorphisms and survival of patients with colorectal cancer (CRC) treated with 5-fluorouracil (5-FU)-based chemotherapy in Taiwan. Methods: We genotyped MTHFR polymorphisms C677T (rs1801133) and A1298C (rs1801131) for 498 CRC patients treated with 5-FU-based chemotherapy after receiving surgery. Survival analyses on MTHFR polymorphisms were performed using log-rank test and Kaplan–Meier curve. Cox proportional hazards models were used to calculate the hazard ratios (HRs) and 95{\%} confidence intervals (CIs) for the association between MTHFR genotypes and survival. Results: Overall survival (OS) was significantly longer in CRC patients with MTHFR 677 CT+TT genotypes compared with those with 677 CC genotype (HR 0.77; 95{\%} CI 0.60–0.98). Although the MTHFR A1298C polymorphism was not associated with OS in CRC, this polymorphism was associated with significantly shorter OS in rectal cancer. Among rectal cancer patients, OS was shorter for patients with AC+CC genotypes than for those with the AA genotype (HR 1.95; 95{\%} CI 1.35–2.83). In haplotype analysis, better OS was found for colon cancer patients carrying the MTHFR 677T-1298A haplotype (HR 0.73; 95{\%} CI 0.55–0.97), but worse survival was linked to rectal cancer patients carrying the MTHFR 677C-1298C haplotype (HR 1.53; 95{\%} CI 1.08–2.18). Conclusions: Our findings suggest that MTHFR genotypes provide prognostic information for CRC patients treated with 5-FU-based chemotherapy.",
keywords = "5-Fluorouracil, Colorectal cancer, MTHFR, Overall survival, Polymorphisms",
author = "Yeh, {Chih Ching} and Lai, {Ching Yu} and Chang, {Shih Ni} and Hsieh, {Ling Ling} and Reiping Tang and Sung, {Fung Chang} and Lin, {Yi Kuei}",
year = "2017",
month = "1",
day = "2",
doi = "10.1007/s10147-016-1080-z",
language = "English",
pages = "1--10",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy

AU - Yeh, Chih Ching

AU - Lai, Ching Yu

AU - Chang, Shih Ni

AU - Hsieh, Ling Ling

AU - Tang, Reiping

AU - Sung, Fung Chang

AU - Lin, Yi Kuei

PY - 2017/1/2

Y1 - 2017/1/2

N2 - Background: This study examined the association between methylenetetrahydrofolate reductase (MTHFR) polymorphisms and survival of patients with colorectal cancer (CRC) treated with 5-fluorouracil (5-FU)-based chemotherapy in Taiwan. Methods: We genotyped MTHFR polymorphisms C677T (rs1801133) and A1298C (rs1801131) for 498 CRC patients treated with 5-FU-based chemotherapy after receiving surgery. Survival analyses on MTHFR polymorphisms were performed using log-rank test and Kaplan–Meier curve. Cox proportional hazards models were used to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between MTHFR genotypes and survival. Results: Overall survival (OS) was significantly longer in CRC patients with MTHFR 677 CT+TT genotypes compared with those with 677 CC genotype (HR 0.77; 95% CI 0.60–0.98). Although the MTHFR A1298C polymorphism was not associated with OS in CRC, this polymorphism was associated with significantly shorter OS in rectal cancer. Among rectal cancer patients, OS was shorter for patients with AC+CC genotypes than for those with the AA genotype (HR 1.95; 95% CI 1.35–2.83). In haplotype analysis, better OS was found for colon cancer patients carrying the MTHFR 677T-1298A haplotype (HR 0.73; 95% CI 0.55–0.97), but worse survival was linked to rectal cancer patients carrying the MTHFR 677C-1298C haplotype (HR 1.53; 95% CI 1.08–2.18). Conclusions: Our findings suggest that MTHFR genotypes provide prognostic information for CRC patients treated with 5-FU-based chemotherapy.

AB - Background: This study examined the association between methylenetetrahydrofolate reductase (MTHFR) polymorphisms and survival of patients with colorectal cancer (CRC) treated with 5-fluorouracil (5-FU)-based chemotherapy in Taiwan. Methods: We genotyped MTHFR polymorphisms C677T (rs1801133) and A1298C (rs1801131) for 498 CRC patients treated with 5-FU-based chemotherapy after receiving surgery. Survival analyses on MTHFR polymorphisms were performed using log-rank test and Kaplan–Meier curve. Cox proportional hazards models were used to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between MTHFR genotypes and survival. Results: Overall survival (OS) was significantly longer in CRC patients with MTHFR 677 CT+TT genotypes compared with those with 677 CC genotype (HR 0.77; 95% CI 0.60–0.98). Although the MTHFR A1298C polymorphism was not associated with OS in CRC, this polymorphism was associated with significantly shorter OS in rectal cancer. Among rectal cancer patients, OS was shorter for patients with AC+CC genotypes than for those with the AA genotype (HR 1.95; 95% CI 1.35–2.83). In haplotype analysis, better OS was found for colon cancer patients carrying the MTHFR 677T-1298A haplotype (HR 0.73; 95% CI 0.55–0.97), but worse survival was linked to rectal cancer patients carrying the MTHFR 677C-1298C haplotype (HR 1.53; 95% CI 1.08–2.18). Conclusions: Our findings suggest that MTHFR genotypes provide prognostic information for CRC patients treated with 5-FU-based chemotherapy.

KW - 5-Fluorouracil

KW - Colorectal cancer

KW - MTHFR

KW - Overall survival

KW - Polymorphisms

UR - http://www.scopus.com/inward/record.url?scp=85007590865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007590865&partnerID=8YFLogxK

U2 - 10.1007/s10147-016-1080-z

DO - 10.1007/s10147-016-1080-z

M3 - Article

SP - 1

EP - 10

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

ER -